Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Catalyst Pharmaceutical Partners, a biopharmaceutical company, has reached the patient enrollment target in its Phase II trial evaluating CPP-109 for the treatment of cocaine addiction.
Subscribe to our email newsletter
CPP-109 is Catalyst’s tablet formulation of vigabatrin being developed as a treatment for cocaine and methamphetamine addiction, as well as other addictions and obsessive-compulsive disorders.
The randomized, double-blind, placebo-controlled clinical trial is assessing safety and efficacy of CPP-109 over a 12 week treatment period, with an additional 12 weeks of follow-up. The specified total of 180 patients have now been enrolled at 11 addiction research facilities across the US. Catalyst expects to have top-line results from the trial during the second quarter of 2009.
Douglas Winship, vice president of regulatory operations at Catalyst, said: “We look forward with great anticipation to the results of this cocaine dependency trial and the opportunity to improve treatment outcomes of such patients everywhere.”